CONFIRMED
Chairman of the Management Board

Hmelnickis J.Hmeļnickis
Olaine, 06.11, 2026

Description of procurement subject ID No. 2026/11/3

1. General information about the customer

Name of customer:	JSC Olpha
Commercial registration No.:	40003007246
Address:	Rupnicu street 5, Olaine, LV-2114, Latvia
Contact person:	Agnese Reitupe, Director of Resources and Development Projects Phone: +371 2940 9499 E-mail: agnese.reitupe@olpha.eu

2. Procurement subject technical specification

Evaluation of antiarrhythmic efficacy.

Additional information about the procurement subject is available from the customer upon written request to the above-indicated e-mail address.

1.	Scope of Work	A preclinical study of the antiarrhythmic efficacy of the test item after continuous infusion in an aconitine-induced arrhythmia model in rats, including: 1) Protocol development; 2) Bioanalytical method development and validation to determine the concentration of the test item in rat plasma (the applicant may use an existing developed and validated method, if available); 3) Preparation of animals for test item administration via minipump continuous infusion, including: - Subcutaneous implantation of a minipump on the back of the rats. The pump outlet catheter is routed through the right internal jugular vein into the cranial vena cava (*v. cava cranialis*); - Filling the minipump with the test item solution (prepared at a concentration and flow rate designed to maintain a continuous 24-hour infusion and achieve a target steady-state plasma concentration); 4) Preparation of animals for test item administration via intravenous bolus injection, including:

		- Surgical catheterization of a jugular vein in the rats. The catheter is tunnelled subcutaneously from the jugular venipuncture site along the side of the neck to an exit point at the scruff (nape of the neck); 5) Test item intravenous dose screening, including: - Single-dose intravenous administration at three (3) dose levels; - At least three (3) animals per dose level; - Electrocardiogram (ECG) screening to monitor the development of arrhythmias and other electrophysiological alterations; 6) Test item pharmacokinetics study, including: - Test item administration (at one (1) dose level) via minipump continuous infusion (Continuous Infusion Cohort: at least six (6) rats); - Test item administration (at one (1) dose level) via intravenous bolus injection (Intravenous Bolus Cohort: at least six (6) rats); - Blood sample collection at up to sixteen (16) time-points for the Continuous Infusion Cohort; - Blood sample collection at up to twelve (12) time-points for the Intravenous Bolus Cohort; - Determination of the test item concentration in the collected plasma samples; - Pharmacokinetic (PK) parameters calculation. 7) Assessment of antiarrhythmic efficacy in an aconitine-induced arrhythmia model in rats, including: - Vehicle control group: animals (at least eight (8) rats) receive the vehicle solution intravenously as a single dose via an implanted jugular vein catheter; - Intravenous bolus group: animals (at least eight (8) rats) receive the test item solution as a single dose (at one (1) dose level) via an implanted jugular vein catheter; - Continuous infusion group: animals (at least eight (8) rats) receive a continuous infusion of the test item (at one (1) dose level) via a subcutaneously implanted minipump; - Procedure: following vehicle administration, test item intravenous bolus injection, or the start of continuous minipump infusion, the animals are anesthetized and surgically catheterized for the intravenous administration of aconitine; - Continuous ECG monitoring until the restoration of normal sinus rhythm or animal death. 8) Evaluation of the study results and preparation of the final report.
2.	Financial proposal requirements	The proposal must include all costs associated with the performance of the services. The proposal shall provide a clear breakdown of the total project costs, separated into service costs and pass-through costs.

3. Requirements for the Applicant

1.	Applicant´s experience	1. The applicant has sufficient experience in conducting preclinical studies of antiarrhythmic efficacy in an aconitine-induced arrhythmia model in rats. 2. The applicant has sufficient experience in test item administration via minipump continuous infusion and intravenous bolus injection. 3. The applicant has sufficient experience in ECG monitoring and results evaluation. 4. The applicant is authorized to carry out the studies in accordance with European Union legislation on the protection of animals used for scientific purposes or their equivalent.
2.	Applicant´s resources	1. The applicant has appropriate scientific staff. 2. The applicant has the necessary technical equipment to carry out the preclinical study in accordance with the requirements of this procurement subject.
3.	Date of completion	The date of completion refers to the final report mutually accepted by both parties - this must be done no later than **30 September 2027.**
4.	Amount of work	The applicant shall apply for all activities presented in this technical specification.
5.	Compliance	In case of possible equivalent to the requirements listed in the description of procurement subject, unforeseen by the customer, the applicant can submit equivalent offer in conformity with requirements. The applicant can also submit the offer, which corresponds to higher (better) requirements.
6.	Price	The total contract amount should be presented in EUR (excluding VAT).
7.	Schedule of payment	The applicant agrees that the final payment conditions will be established in the contract. The applicant may indicate a preferred payment schedule in the application.
8.	Documents / information to be submitted	1. Details of the proposed study design. 2. Copies of documents verifying the applicant's legal status.
9.	Requirements for offer preparation	1. Offer shall be submitted in accordance with the form "Technical Offer" in Annex no. 1 to the Description of procurement subject. 2. Offer shall be written in English or Latvian languages. 3. Indicate the date of preparation of the document, place and signature with a clarification, as well as the company's legal address and registration number. 4. The signed offer should be sent to: Agnese Reitupe, Director of Resources and Development Projects, e-mail: agnese.reitupe@olpha.eu

Annex no.1: Technical offer form on 5 (five) pages.

This procurement is organized within the framework of project No. 5.1.1.2.i.0/2/24/A/CFLA/005

Annex no.1
to the Description of procurement subject

[Applicant name]
Registration number: [ ]
Address: [ ]

[Place], [Date]
No. _____

Offer

1.	**Customer**	JSC Olpha	
2.	**Customer address**	Rupnicu street 5, Olaine, LV-2114, Latvia	
3.	**Procurement subject**	Evaluation of antiarrhythmic efficacy	
4.	**Place of study conduct**	*[Applicant address]*	
5.	**Information about applicant**	*[Short description of the applicant]*	
6.	**Description of procurement subject**		
		Requirements	Offer
6.1	Scope of work	A preclinical study of the antiarrhythmic efficacy of the test item after continuous infusion in an aconitine-induced arrhythmia model in rats, including: 1) Protocol development; 2) Bioanalytical method development and validation to determine the concentration of the test item in rat plasma (the applicant may use an existing developed and validated method, if available); 3) Preparation of animals for test item administration via minipump continuous infusion, including: - Subcutaneous implantation of a minipump on the back of the rats. The pump outlet catheter is routed through the right internal jugular vein into the cranial vena cava (*v. cava cranialis*); - Filling the minipump with the test item solution (prepared at a concentration and flow rate designed to	

		maintain a continuous 24-hour infusion and achieve a target steady-state plasma concentration); 4) Preparation of animals for test item administration via intravenous bolus injection, including: - Surgical catheterization of a jugular vein in the rats. The catheter is tunnelled subcutaneously from the jugular venipuncture site along the side of the neck to an exit point at the scruff (nape of the neck); 5) Test item intravenous dose screening, including: - Single-dose intravenous administration at three (3) dose levels; - At least three (3) animals per dose level; - Electrocardiogram (ECG) screening to monitor the development of arrhythmias and other electrophysiological alterations; 6) Test item pharmacokinetics study, including: - Test item administration (at one (1) dose level) via minipump continuous infusion (Continuous Infusion Cohort: at least six (6) rats); - Test item administration (at one (1) dose level) via intravenous bolus injection (Intravenous Bolus Cohort: at least six (6) rats); - Blood sample collection at up to sixteen (16) time-points for the Continuous Infusion Cohort; - Blood sample collection at up to twelve (12) time-points for the Intravenous Bolus Cohort;	

		- Determination of the test item concentration in the collected plasma samples; - Pharmacokinetic (PK) parameters calculation. 7) Assessment of antiarrhythmic efficacy in an aconitine-induced arrhythmia model in rats, including: - Vehicle control group: animals (at least eight (8) rats) receive the vehicle solution intravenously as a single dose via an implanted jugular vein catheter; - Intravenous bolus group: animals (at least eight (8) rats) receive the test item solution as a single dose (at one (1) dose level) via an implanted jugular vein catheter; - Continuous infusion group: animals (at least eight (8) rats) receive a continuous infusion of the test item (at one (1) dose level) via a subcutaneously implanted minipump; - Procedure: following vehicle administration, test item intravenous bolus injection, or the start of continuous minipump infusion, the animals are anesthetized and surgically catheterized for the intravenous administration of aconitine; - Continuous ECG monitoring until the restoration of normal sinus rhythm or animal death. 8) Evaluation of the study results and preparation of the final report.	
6.2	Financial proposal requirements	The proposal must include all costs associated with the performance of the services. The proposal shall provide a clear breakdown of the total project costs, separated into	

		service costs and pass-through costs.	
7.	**Criteria for selection of offers**		
7.1.	Applicant´s experience	1. The applicant has sufficient experience in conducting preclinical studies of antiarrhythmic efficacy in an aconitine-induced arrhythmia model in rats. 2. The applicant has sufficient experience in test item administration via minipump continuous infusion and intravenous bolus injection. 3. The applicant has sufficient experience in ECG monitoring and results evaluation. 4. The applicant is authorized to carry out the studies in accordance with European Union legislation on the protection of animals used for scientific purposes or their equivalent.	
7.2.	Applicant´s resources	1. The applicant has appropriate scientific staff. 2. The applicant has the necessary technical equipment to carry out the preclinical study in accordance with the requirements of this procurement subject.	
7.3.	Date of completion	The date of completion refers to the final report mutually accepted by both parties - this must be done no later than **30 September 2027.**	
7.4.	Amount of work	The applicant shall apply for all activities presented in this technical specification.	
7.5.	Compliance	In case of possible equivalent to the requirements listed in the description of procurement subject,	

		unforeseen by the customer, the applicant can submit equivalent offer in conformity with requirements. The applicant can also submit the offer, which corresponds to higher (better) requirements.	
7.6.	Price	The total contract amount should be presented in EUR (excluding VAT).	
7.7.	Schedule of payment	The applicant agrees that the final payment conditions will be established in the contract. The applicant may indicate a preferred payment schedule in the application.	
7.8.	Documents/ information to be submitted	1. Details of the proposed study design. 2. Copies of documents verifying the applicant's legal status.	

[Company Name]
[Position] _____ [Signature, Name, Surname]